Cargando…
Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review
Chronic lymphocytic leukemia (CLL), which is the most common type of leukemia in western countries in adults, is characterized by heterogeneity in clinical course, prognosis and response to the treatment. Although, in recent years a number of factors with probable prognostic value in CLL have been i...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886107/ https://www.ncbi.nlm.nih.gov/pubmed/33603488 http://dx.doi.org/10.2147/CMAR.S283903 |
_version_ | 1783651728616325120 |
---|---|
author | Stefaniuk, Paulina Onyszczuk, Julia Szymczyk, Agnieszka Podhorecka, Monika |
author_facet | Stefaniuk, Paulina Onyszczuk, Julia Szymczyk, Agnieszka Podhorecka, Monika |
author_sort | Stefaniuk, Paulina |
collection | PubMed |
description | Chronic lymphocytic leukemia (CLL), which is the most common type of leukemia in western countries in adults, is characterized by heterogeneity in clinical course, prognosis and response to the treatment. Although, in recent years a number of factors with probable prognostic value in CLL have been identified (eg NOTCH1, SF3B1 and BIRC-3 mutations, or evaluation of microRNA expression), TP53 aberrations are still the most important single factors of poor prognosis. It was found that approximately 30% of all TP53 defects are mutations lacking 17p13 deletion, whereas sole 17p13 deletion with the absence of TP53 mutation consists of 10% of all TP53 defects. The detection of del(17)(p13) and/or TP53 mutation is not a criterion itself for starting antileukemic therapy, but it is associated with an aggressive course of the disease and poor response to the standard chemoimmunotherapy. Treatment of patients with CLL harbouring TP53-deficiency requires drugs that promote cell death independently of TP53. Novel and smarter therapies revolutionize the treatment of del(17p) and/or aberrant TP53 CLL, but development of alternative therapeutic approaches still remains an issue of critical importance. |
format | Online Article Text |
id | pubmed-7886107 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-78861072021-02-17 Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review Stefaniuk, Paulina Onyszczuk, Julia Szymczyk, Agnieszka Podhorecka, Monika Cancer Manag Res Review Chronic lymphocytic leukemia (CLL), which is the most common type of leukemia in western countries in adults, is characterized by heterogeneity in clinical course, prognosis and response to the treatment. Although, in recent years a number of factors with probable prognostic value in CLL have been identified (eg NOTCH1, SF3B1 and BIRC-3 mutations, or evaluation of microRNA expression), TP53 aberrations are still the most important single factors of poor prognosis. It was found that approximately 30% of all TP53 defects are mutations lacking 17p13 deletion, whereas sole 17p13 deletion with the absence of TP53 mutation consists of 10% of all TP53 defects. The detection of del(17)(p13) and/or TP53 mutation is not a criterion itself for starting antileukemic therapy, but it is associated with an aggressive course of the disease and poor response to the standard chemoimmunotherapy. Treatment of patients with CLL harbouring TP53-deficiency requires drugs that promote cell death independently of TP53. Novel and smarter therapies revolutionize the treatment of del(17p) and/or aberrant TP53 CLL, but development of alternative therapeutic approaches still remains an issue of critical importance. Dove 2021-02-12 /pmc/articles/PMC7886107/ /pubmed/33603488 http://dx.doi.org/10.2147/CMAR.S283903 Text en © 2021 Stefaniuk et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Stefaniuk, Paulina Onyszczuk, Julia Szymczyk, Agnieszka Podhorecka, Monika Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review |
title | Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review |
title_full | Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review |
title_fullStr | Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review |
title_full_unstemmed | Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review |
title_short | Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review |
title_sort | therapeutic options for patients with tp53 deficient chronic lymphocytic leukemia: narrative review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886107/ https://www.ncbi.nlm.nih.gov/pubmed/33603488 http://dx.doi.org/10.2147/CMAR.S283903 |
work_keys_str_mv | AT stefaniukpaulina therapeuticoptionsforpatientswithtp53deficientchroniclymphocyticleukemianarrativereview AT onyszczukjulia therapeuticoptionsforpatientswithtp53deficientchroniclymphocyticleukemianarrativereview AT szymczykagnieszka therapeuticoptionsforpatientswithtp53deficientchroniclymphocyticleukemianarrativereview AT podhoreckamonika therapeuticoptionsforpatientswithtp53deficientchroniclymphocyticleukemianarrativereview |